Journal of Neural Transmission

, Volume 33, Issue 2, pp 163–178 | Cite as

The balance of biogenic amines as condition for normal behaviour

  • W. Birkmayer
  • W. Danielczyk
  • E. Neumayer
  • P. Riederer


An accumulation of norepinephrin, serotonin and dopamin exists in the brainstem. A decrease of biogenic amines in the brains of Parkinson's cases has been demonstrated. A substitution by the precursor L-DOPA produces an increase of dopamin in the brain and a decrease of serotonin. The high level of dopamin improves the akinesia and the depletion of serotonin causes a toxic delir. A substitution by l-tryptophan restores the balance and the Dopa-psychosis disappears.


Public Health Serotonin Biogenic Amine Normal Behaviour Norepinephrin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ajuriaguerra, J. de.: Symposium Bel-Air IV., Genève, Sept. 1970. Monoamines Noyaux gris centraux et Syndrome de Parkinson, p. 327–353. Paris: Masson. 1971.Google Scholar
  2. Amin, A. M., T. B. B. Crawford, andJ. U. Gaddum: The distribution of 5 OH tryptamin and substance P in the central nervous system. Abstr. XIX int. physiol. Congr., p. 165 (1953).Google Scholar
  3. Andńt, N. E., B. E. Ross, andB. Werdinius: On the Occurence of Homovanillic Acid in Brain and Cerebrospinal Fluid and its Determination by a Fluorometric Method. Life Science7, 448 (1963).Google Scholar
  4. Anderson, M., andG. Guerra: Wahnsyndrome im Verlauf des encephalitischen Parkinson. Rass. Neuropsychiatr.5, 22–44 (1951).Google Scholar
  5. Ashcroft, G. W., T. B. B. Crawford, D. Eccleston, D. Sharman, andD. F. McDougalb: 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatr. neurol. diseases. LancetII, 1049–1052 (1966).Google Scholar
  6. Ashcroft, G. W., andD. F. Sharman: Drug-induced Changes in the Concentration of 5-OR Indolyl Compounds in Cerebrospinal Fluid and Caudate Nucleus. Brit. J. Pharmacol.19, 153–160 (1962).PubMedGoogle Scholar
  7. Barbeau, A.: L-DOPA therapy in Parkinson's disease: a critical review of nine years' experience. Canad. Med. Assoc.101, 791–800 (1969).Google Scholar
  8. Bartholini, G., H. M. Bates, W. P. Burkhard, andA. Pletscher: Increase of cerebral catecholamines by 3,4-dihydroxyphenylalanine after Inhibition of peripheral decarboxylase. Nature (London)215, 852–853 (1967).Google Scholar
  9. Bartholini, G., M. Da Prada, andA. Pletscher: Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J. Pharm. Pharmac.20, 228–229 (1968).Google Scholar
  10. Bernheimer, H., W. Birkmayer, andO. Hornykiewicz: Verteilung des 5-hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinsonsyndrom. Klin. Wsehr.39, 1056–1059 (1961).Google Scholar
  11. Bernheimer, H., W. Birkmayer, andO. Hornykiewicz: Zur Biochemie dt Parkinson-Syndroms des Menschen. Klin. Wschr.41, 465–469 (1963)Google Scholar
  12. Birkmayer, W., andO. Hornykiewicz: Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinese. Wien. klin. Wschr.73, 787–788 (1961).PubMedGoogle Scholar
  13. Birkmayer, W., andO. Hornykiewicz: Der L-Dioxyphenylalanin (L-DOPA) Effekt beim Parkinsonsyndrom des Menschen. Arch. Psychiatr.203, 560–574 (1962).Google Scholar
  14. Birkmayer, W.: Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien. Z. f. Nervenheilk.23, 128–139 (1966).Google Scholar
  15. Birkmayer, W.: Die Bedeutung des Monoamin-Metabolismus für die Pathologie des extrapyramidalen Systems. Ars medici57, 814–825 (1967).Google Scholar
  16. Birkmayer, W., andM. Mentasti: Weitere experimentelle Untersuchungen über den Catecholaminstoffwechsel bei extrapyramidalen Erkrankungen Arch. Psychiatr.210, 29–35 (1967).Google Scholar
  17. Birkmayer, W.: Biochemistry of Depression in Parkinson's Disease. In:Barbeau, A., andF. H. McDowell (eds.) L-DOPA and Parkinsonism, p. 341–342. Philadelphia: Fa. Davis. 1970.Google Scholar
  18. Birkmayer, W., andW. Linauer: Störung des Tyrosin- und Tryptophan-metabolimus bei Depression. Arch. Psychiatr. Nervenkr.213, 377–387 (1970).PubMedGoogle Scholar
  19. Birkmayer, W.: 10 Jahre L-DOPA Therapie des Parkinsonsyndroms. Wien, klin. Wschr.83, 221–227 (1971).Google Scholar
  20. Birkmayer, W., W. Danielczyk, E. Neumayer, andP. Riederer. (In press.)Google Scholar
  21. Bostroem, A.: Zum Verständnis gewisser psychischer Veränderungen bei Kranken mit Parkinsonschem Symptomenkomplex. Z. ges. Neurol. Psychiat.76, 444–460 (1922).Google Scholar
  22. Bunney, W. E., D. S. Janowsky, F. K. Goodwin, J. M. Davis, M. K. H. Brodie, D. L. Murphy, andT. N. Chase: Effect of L-DOPA on depression. LancetI, 885–886 (1969).Google Scholar
  23. Bürger, H., andW. Mayer-Gross: Schizophrene Psychosen bei Encephalitis lethargica. Z. Neurol. Psychiat.106, 438–482 (1926).Google Scholar
  24. Calne, D. B., A. S. D. Spiers., G. M. Stern, D. R. Laurence, andR. Armitoge: L-DOPA in idiopathic parkinsonism. Lancet2, 973–976 (1969).PubMedGoogle Scholar
  25. Carlsson, A., M. Lindqvist, T. Magnusson, andB. Waldeck: On the presence of 3-hydroxytyramine in brain. Science127, 471–473 (1958).PubMedGoogle Scholar
  26. Celesia, G. G., andA. N. Barr: Psychosis and other psychiatric manifestations of levodopa therapy. Arch. Neurol.23, 193–200 (1970).PubMedGoogle Scholar
  27. Cherrington, M.: Parkinsonism, L-DOPA and mental depression. J. Americ. Geriat. Soc.18, 513–516 (1970).Google Scholar
  28. Clark, W. G.: Some aspects of the psychic and behavioral effects of L-DOPA. p. 349–357. In: L-DOPA and Parkinsonism (Barbeau, A., andF. H. McDowell, eds.). Philadelphia: Fa. Davis. 1970.Google Scholar
  29. Coppen, A., D. M. Shaw, A. Mallerson, E. Eccleston, andG. Gundy: Tryptamine metabolism in depression.Brit.J.Psychia.111, 993–998 (1965).Google Scholar
  30. Coppen, A., D. M. Shaw, B. Herzberg, andR. Maggs: Tryptophan in the treatment of depression. Lancet2, 1178–1180 (1967).PubMedGoogle Scholar
  31. Cotzias, G. C., M. H. van Woert, andL. M. Schiffer: Aromatic amino acids and modification of parkinsonism. New Eng. J.Med.276, 374–379 (1967).PubMedGoogle Scholar
  32. Cotzias, G. C., D. S. Papavasiliou, andR. Gellen: Modification of parkinsonism: chronic treatment with L-DOPA. New Eng. J. Med.280, 337–345 (1969).PubMedGoogle Scholar
  33. Damasio, A. R., J. L. Antunes, andC. Macedo: L-DOPA, Parkinsonism and Depression. LancetII, 611–612 (1970).Google Scholar
  34. Domarus, E.: Über halluzinatorisch-paranoide Bilder bei Metencephalitis. Arch. Psychiatr.78, 558–570 (1926).Google Scholar
  35. Economo, C. v.: Die Encephalitis lethargica, ihre Nachkrankheiten und ihre Behandlung. Wien: Urban <Schwarzenberg. 1929.Google Scholar
  36. Ehringer, H., andO. Hornykiewicz: Verteilung von Noradrenalin und Dopamin (3-Hydroxytryptamin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wschr.38, 1236–1240 (1960).PubMedGoogle Scholar
  37. Euler, V. S. v.: A specific Sympathomimetic Ergone in Adrenergic Nerve Fibres and its Relations to Adrenaline and Nor Adrenaline. Acta Physiol. Scand.12, 73–97 (1946).Google Scholar
  38. Everett, G. M., andJ. W. Borcherding: L-DOPA: Effect on Concentrations of Dopamine, Norepinephrine and Serotonin in Brains of Mice. Science6, 849–850 (1970).Google Scholar
  39. Goodwin, F. K., H. K. H. Brodie, D. L. Murphy, andW. E. Bunney: Administration of a peripheral decarboxylase inhibitor with L-DOPA to depressed patients. LancetI, 908–911 (1970).Google Scholar
  40. Goodwin, F. K.: Psychiatric Side Effects of Levodopa in Man. JAMA218, 1915–1919 (1971).PubMedGoogle Scholar
  41. Jenkins, R. B., andR. H. Groh: Mental symptoms in Parkinsonian patients treated with L-DOPA. LancetII, 177–180 (1970).Google Scholar
  42. König, H.: Zur Psychopathologie der Paralysis agitans. Arch. Psychiatr.50, 285–305 (1912).Google Scholar
  43. Lenz, H.; Die Dissoziation der Schlafkomponenten beim Parkinsonsyndrom. Arch. Psychiatr.194, 550–559 (1956).Google Scholar
  44. Leonhard, K.: Partielle Schlaf zustände mit Halluzinationen beim Parkinson. Z. Neur.131, 234–264 (1931).Google Scholar
  45. Leyser, E.: Über die Differentialdiagnose metencephalitischer und schizophrener Störungen. Z. Neur.99, 424–438 (1929).Google Scholar
  46. Lhermitte, J.: Syndrome de la calotte du pédoncule cérébral. Rev. neurol.38, 1359–1365 (1922).Google Scholar
  47. Malitz, S., andM. Kanzler: L-DOPA-Behavioural Effects. In:Ajuriaguerra, J. de: Symposium Bel-Air IV. Monoamines noyaux gris centraux et Syndrome de Parkinson, p. 467–484. Paris: Masson. 1971.Google Scholar
  48. Maillé, A. H.: Les troubles psychiques chez les parkinsoniens. Thèse Bordeaux. 1908.Google Scholar
  49. Matussek, N., O. Benkert, K. Schneider, H. Otten, andH. Pohlmeier: L-DOPA plus Decarboxylase Inhibitor in Depression. LancetII, 660–661 (1970).Google Scholar
  50. McDowell, F., J. E. Lee, T. Swift, R. D. Sweet, J. S. Ogsbury, andJ. T. Kessler: Treatment of Parkinson's syndrome with L-dihydroxyphenylalanine (levodopa). Ann. Intern. Med.72, 29–35 (1970).PubMedGoogle Scholar
  51. Meunter, M. D.: Double-blind placebo-controlled study of levodopa therapy in Parkinson's disease. Neurology20, 6–13 (1970).Google Scholar
  52. Ng, K. Y., T. N. Chase, R. W. Cobitrn, andI. J. Kopin: L-DOPA-induced release of cerebral monoamines. Science170, 76–77 (1970).PubMedGoogle Scholar
  53. O'Brien, C. P., J. N. DiGiacomo, S. Fahn, andG. A. Schwarz: Mental Effects of High-Dosage-Levodopa. Arch. Gen.Psychiat.24, 61–64 (1971).PubMedGoogle Scholar
  54. Schildkraut, J. J.: The catecholamine hypothesis of affective disorders. Amer. J. Psychiat.123, 508–522 (1965).Google Scholar
  55. Siegfried, J.: Traitement du Parkinsonisme avec la L-DOPA associée à un inhibiteur de la decarboxylase. Méd. et Hyg.27, 543–545 (1969).Google Scholar
  56. Timberlake, W. H.: Double-blind comparison of levodopa and procyclidine in Parkinsonism. Neurology20, 31–35 (1970).Google Scholar
  57. Tissot, R., J. M. Gaillard, M. Guggisberg, G. Gauthier, andJ. Ajuriaguerra: Therapeutique du syndrome de Parkinson par la L-DOPA “per os” associée à un inhibiteur de la décarboxylase (Ro 4-4602). Press méd.77, 616–622 (1969).Google Scholar
  58. Twarog, B. M., andJ. H. Page: Serotonin Content of some Mammalian Tissues and Urine and a Method for its Determination. J. Physiol.175, 157–161 (1953).Google Scholar
  59. Vogt, M.: The concentration of sympathin in different parts of the central nervous system. J. Physiol.123, 451–481 (1954).PubMedGoogle Scholar
  60. Yahr, M. D., R. S. Duvoisin, M. J. Schear, R. E. Barret, andM. M. Hoehn: Treatment of Parkinsonism with levodopa. Arch. Neurol. (Chic.)21, 343–354 (1969).Google Scholar

Copyright information

© Springer-Verlag 1972

Authors and Affiliations

  • W. Birkmayer
    • 1
  • W. Danielczyk
    • 1
  • E. Neumayer
    • 1
  • P. Riederer
    • 1
  1. 1.Ludwig-Boltzmann-Institut für Neurochemie und neurologische Abteilung des Alterskrankenhauses der Stadt Wien-LainzÖsterreich

Personalised recommendations